BioSpace News Archive

IRADIMED CORPORATION announced that the Company will release its 2020 second quarter financial results before the market opens on Thursday, July 30th.

Investment to Drive Company Growth, Innovation & Expansion Across Patient Care Continuum

AngioDynamics, Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced financial results for the fourth quarter of fiscal year 2020, which ended May 31, 2020.

Biodesix, Inc., a leader in lung cancer diagnostics, announced the publication of research findings on a diagnostic test capable of generating valuable data to help guide the treatment of patients with advanced non-small cell lung cancer.

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific antibodies, announces further progress in its long-standing immuno-oncology collaboration with Merck KGaA, Darmstadt, Germany.

Multi-center dose escalation and expansion study will assess safety, tolerability and preliminary efficacy of treatment with ONCR-177 alone and in combination with Merck’s KEYTRUDA® (pembrolizumab)

LONDON and NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that at the Annual General Meeting of the Company held at 10.00 a.m. on 16 July 2020, all of the resolutions were duly passed. The results of the proxy voting will be available shortly on the

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary revenue results for the three months ended June 30, 2020. Management Commentary: “While our second quarter revenue performance was significantly impacted by the COVID-19 global pandemic, we are pleased to see our business trends improve during the second quarter along with the gradual reopening of practi

- Financial and operational leader brings deep expertise from across clinical and commercial stage biopharmaceutical companies

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter ended June 30, 2020, and provide an update on recent business highlights, on July 30, 2020. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss the